Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Thromb Haemost ; 13(10): 1854-66, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26270243

ABSTRACT

BACKGROUND: Endothelial von Willebrand factor (VWF) inhibits angiogenesis. Accordingly, blood outgrowth endothelial cells (BOECs) isolated from von Willebrand disease (VWD) patients showed enhanced in vitro angiogenesis when compared with healthy control BOECs. Characterization of the angiogenic response of VWD BOECs is limited and differences between the different types of VWD have not been investigated in detail. OBJECTIVES: The aim of this study was to further explore the potential pathogenic effect of VWF mutations on angiogenesis. METHODS: BOECs were isolated from four healthy individuals, 10 patients with VWD and one heterozygous carrier of a type 2N mutation. Cell migration and tube formation were measured. RESULTS: Migration velocity and total tube formation were similar between VWD patients and controls in general. BOECs from the type 3 VWD patient and one type 2B patient showed increased migratory velocity and tube formation compared with BOECs from other patients and healthy controls. Directional migration was impaired in eight out of 10 VWD BOECs and the ability to form tubes was limited to early passage numbers, but not for BOECs from healthy controls. CONCLUSION: BOECs can be a useful tool for ex vivo assessment of endothelial cell function in patients with different types of VWD, but possible limitations, such as early loss of angiogenic capacity, should be recognized. BOECs from most VWD patients consistently showed impairment in the directionality of migration. This is the first report on angiogenic properties of a type 3 VWD BOEC, which showed increased in vitro angiogenesis.


Subject(s)
Endothelial Cells/metabolism , Neovascularization, Physiologic , von Willebrand Diseases/blood , von Willebrand Factor/metabolism , Case-Control Studies , Cell Movement , Cell Separation , Cells, Cultured , Genetic Predisposition to Disease , Heterozygote , Humans , Mutation , Neovascularization, Physiologic/genetics , Phenotype , Signal Transduction , von Willebrand Diseases/genetics , von Willebrand Diseases/physiopathology , von Willebrand Factor/genetics
2.
J Thromb Haemost ; 13(4): 592-600, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25650553

ABSTRACT

BACKGROUND: One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated. OBJECTIVES: To determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF. METHODS: Three type 3 von Willebrand disease (VWD) patients were infused with Haemate-P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF-deficient mice were injected with purified plasma-derived human VWF obtained from donors with either blood group A, blood group B, or blood group O. RESULTS: In mice, we found no difference in clearance rate between plasma-derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate-P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two-fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient. CONCLUSION: There is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non-blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself.


Subject(s)
ABO Blood-Group System/blood , von Willebrand Disease, Type 3/blood , von Willebrand Factor/metabolism , Animals , Biomarkers/blood , Drug Combinations , Factor VIII/administration & dosage , Female , Humans , Infusions, Intravenous , Male , Mice, Inbred C57BL , Mice, Knockout , Protein Binding , Time Factors , von Willebrand Disease, Type 3/diagnosis , von Willebrand Disease, Type 3/drug therapy , von Willebrand Factor/administration & dosage , von Willebrand Factor/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...